BAY 3018250, Placebo equals test product, except active substance clinical trials

(21751) First-in-human single dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3018250 in healthy men in a randomized, placebo-controlled, single-blind, group-comparison design

This early-stage study is looking at a new medicine called BAY 3018250 for treating strokes. It's the very first time this medicine is being given to people. We want to check if it's safe and how the body handles it in healthy men.